Anti-CD4 [CE9.1 (Clenoliximab)]

Absolute Antibody

Anti-CD4 [CE9.1 (Clenoliximab)]

9

The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 ug/ml.

The antibody binds specifically to CD4, a molecule which is part of the immunolgobulin super-family, expressed on the surface of helper T cells. The CD4 molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as primatized, as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and gamma4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec.

Flow Cytometry, ELISA, ImmunoHistoChemistry, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

CE9.1 (Clenoliximab)

CD4

CD4 molecule

CD4 antigen (p55); CD4 receptor; CD4mut; IMD79; OKT4D; T-cell surface antigen T4/Leu-3; T-cell surface glycoprotein CD4

Mouse

IgG1

T-cell surface glycoprotein CD4

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques.

Human, Primate

-20°C,2°C to 8°C

12352203